학술논문
The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.
Document Type
Journal Article
Source
Subject
*AIDS prevention
*HIV infection transmission
*HEMOPHILIA treatment
*VIRAL hepatitis
*BLOOD coagulation factors
*DRUG adulteration
*PRODUCT safety
*COST analysis
*PREVENTION
*INFECTIOUS disease transmission
*
*
*
*
*
*
*
*
*
Language
ISSN
0098-7484
Abstract
Treatment of hemophilia, although greatly improved in recent years, continues to be problematic owing to infectious complications of blood product replacement therapy. This report examines the therapeutic options presently available for the treatment of hemophilia, focusing on the potential for repeated viral exposure to influence the progression of infectious disease, decreased risks of viral transmission with blood products produced using newer viral inactivation procedures, higher economic costs of newer blood products, and the current inadequate supply of blood products in the United States. [ABSTRACT FROM AUTHOR]